Production of Medically Important Radionuclides 52 Mn and 90 Nb
Over the final reporting period of this project, we at MGH finalized our effort on Project 2: Production and Characterization of 90 Nb which, as per our previous report led us to an interesting application of mass spectrometry in radiometal chemistry. Overall, our research has developed parameters and procedures for delivering high 90 Nb for preclinical and translational applications by initializing the cyclotron targetry and separation chemistry for delivering 90 Nb in a chemical form suitable for subsequent development of 90 Nb-based PET radiotracers, and most recently we have published on the mass spectrometry applications described in the present report. We have been working with MSKCC (PI Jason Lewis) on the 90 Nb methodology and have had input from UAB (PI Suzy Lapi). An in-person meeting was held during the upcoming funding period with 2 PIs who are co-organizing the Radiochemistry Symposium (Lapi and Vasdev) and Program Director Dr. Ethan Balkin, during the ACS National Meeting in March 2018, and 2 PIs (Lewis and Vasdev) co presented in at the World Federation of Nuclear Medicine and Biology at a symposium sponsored by the Australian Nuclear Sciences and Technology Organisation, where they are both collaborating, in Melbourne, Australia in April 2018. Future projects and collaborations are under discussion with the Lapi lab to focus on new applications of 76 Br chemistry, and a new collaboration has already resulted with the Lewis lab on 18 F radiochemistry that employ iodonium ylide based precursors developed in the Vasdev lab, for clinical production of [ 18 F]MFBG. It is noteworthy that the PI has now relocated to the University of Toronto and has 2 cyclotrons (IBA Cyclone and Scanditronix MC-17) that will also be used to explore new 11 C-radiochemistry including [ 11 C]CO.